Renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Williams, Richard T ^a   Yu, Alice L ^a,b,c   Diccianni, Mitchell B ^a   Theodorakis, Emmanuel A ^a   Batova, Ayse ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Autophagy; Englerin A; Necrosis; Renal cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; AUTOPHAGY; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; KIDNEY NEOPLASMS; PHOSPHORYLATION; SESQUITERPENES, GUAIANE;

EID: 84884285360     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-57     Document Type: Article

References (51)

1. The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program. Nguyen MM, Gill IS, Ellison LM, J Urol 2006 176 6 Pt 1 2397 400 17085111 (Pubitemid 44755062)
2. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Amato RJ, Ann Oncol 2005 16 1 7 15 10.1093/annonc/mdi002 15598929 (Pubitemid 40124470)
3. Targeted molecular therapy for renal cell carcinoma. Lane BR, Rini BI, Novick AC, Campbell SC, Urology 2007 69 1 3 10 17280906 (Pubitemid 46161691)
4. Update on targeted therapies for clear cell renal cell carcinoma. Singer EA, Gupta GN, Srinivasan R, Curr Opin Oncol 2011 23 3 283 9 10.1097/CCO. 0b013e32834479c0 21330923
5. Mutations of the VHL tumour suppressor gene in renal carcinoma. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, et al. Nat Genet 1994 7 1 85 90 10.1038/ng0594-85 7915601 (Pubitemid 24232386)
6. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Mukeria A, Holcatova I, Schmidt LS, Toro JR, Karami S, Hung R, Gerard GF, Linehan WM, Merino M, Zbar B, Boffetta P, Brennan P, Rothman N, Chow WH, Waldman FM, Moore LE, Clin Cancer Res 2008 14 15 4726 34 10.1158/1078-0432.CCR-07-4921 18676741
7. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, Nagashima Y, Kitamura H, Latif F, Zbar B, et al. Cancer Res 1994 54 11 2852 5 8187067
8. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Semenza GL, Annu Rev Cell Dev Biol 1999 15 551 578 10.1146/annurev.cellbio.15.1. 551 10611972 (Pubitemid 32250386)
9. Hypoxia, gene expression, and metastasis. Chan DA, Giaccia AJ, Cancer Metast Rev 2007 26 2 333 339 10.1007/s10555-007-9063-1 (Pubitemid 47101666)
10. VHL and HIF signalling in renal cell carcinogenesis. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruïne AP, J Pathol 2010 221 2 125 38 10.1002/path.2689 20225241
11. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Clark PE, Kidney Int 2009 76 9 939 945 10.1038/ki.2009.296 19657325
12. Novel agents in renal carcinoma: a reality check. Najjar YG, Rini BI, Ther Adv Med Oncol 2012 4 4 183 194 10.1177/1758834012443725 22754592
13. Medicinal plants: Traditions of yesterday and drugs of tomorrow. Gurib-Fakim A, Mol Aspects Med 2006 27 1 1 93 10.1016/j.mam.2005.07.008 16105678 (Pubitemid 41790645)
14. Natural products: A continuing source of novel drug leads. Cragg G, Newmann DJ, Biochim Biophys Acta 2013 1830 6 3670 95 10.1016/j.bbagen.2013.02. 008 23428572
15. A review of the plants of the genus Phyllanthus: Their chemistry, pharmacology, and therapeutic potential. Calixto JB, Santos ARS, Filho VC, Yunes RA, Med Res Rev 1998 18 4 189 296 10.1002/(SICI)1098-1128(199807)18:4<189:: AID-MED1>3.0.CO;2-R 9664290
16. Englerin A, a selective inhibitor of renal cancer cell growth, from phyllanthus engleri. Ratnayake R, Covell D, Ransom TT, Gustafson KR, Beutler JA, Org Lett 2009 11 1 57 60 10.1021/ol802339w 19061394
17. Total synthesis: towards artificial terpene cyclases. Willot M, Christmann M, Nat Chem 2010 2 7 519 520 10.1038/nchem.715 20571563
18. Synthetic strategies toward the guaiane sesquiterpene englerin A. Chain WJ, Synlett 2011 18 2605 2608
19. Chemical synthesis of the englerins. Pouwer RH, Richard JA, Tseng CC, Chen DY, Chem Asian J 2012 7 1 22 35 10.1002/asia.201100780 22162365
20. Progresses in total synthesis of englerin A and biological evaluations of its analogues. Lu YY, Yao HQ, Sun BF, Chin J Org Chem 2012 32 1 1 12 10.6023/cjoc1110141
21. Formal synthesis of (-)-englerin A and cytotoxicity studies of truncated englerins. Xu J, Caro-Diaz EJ, Batova A, Sullivan SD, Theodorakis EA, Chem Asian J 2012 7 5 1052 60 10.1002/asia.201101021 22415793
22. Englerin A selectively induces necrosis in human renal cancer cells. Sulzmaier FJ, Li Z, Nakashige ML, Fash DM, Chain WJ, Ramos JW, PLoS One 2012 7 10 48032 10.1371/journal.pone.0048032 23144724
23. Englerin A stimulates PKCθ to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality. Sourbier C, Scroggins BT, Ratnayake R, Prince TL, Lee S, Lee MJ, Nagy PL, Lee YH, Trepel JB, Beutler JA, Linehan WM, Neckers L, Cancer Cell 2013 23 2 228 37 10.1016/j.ccr.2012.12.007 23352416
24. Regulation of Vinca alkaloid-induced apoptosis by NF-κB/IκB pathway in human tumor cells. Huang Y, Fang Y, Wu J, Dziadyk JM, Zhu X, Sui M, Fan W, Mol Cancer Ther 2004 3 3 271 277 15026547 (Pubitemid 39193702)
25. Association of active caspase 8 with the mitochondrial membrane during apoptosis: potential roles in cleaving BAP31 and caspase 3 and mediating mitochondrion-endoplasmic reticulum cross talk in etoposide-induced cell death. Chandra D, Choy G, Deng X, Bhatia B, Daniel P, Tang DG, Mol Cell Biol 2004 24 15 6592 607 10.1128/MCB.24.15.6592-6607.2004 15254227 (Pubitemid 38944340)
26. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms: intermediacy of H(2)O(2)- and p53-dependent pathways. Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B, J Biol Chem 2004 279 24 25535 43 10.1074/jbc.M400944200 15054096 (Pubitemid 38756813)
27. Camptothecin- and etoposide-induced apoptosis in human leukemia cells is independent of cell death receptor-3 and -4 aggregation but accelerates tumor necrosis factor-related apoptosis-inducing ligand-mediated cell death. Bergeron S, Beauchemin M, Bertrand R, Mol Cancer Ther 2004 3 12 1659 69 15634660 (Pubitemid 40136722)
28. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, Fan Y, Nelson DA, Jin S, White E, Cancer Cell 2006 10 1 51 64 10.1016/j.ccr.2006.06.001 16843265
29. Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Pan T, Rawal P, Wu Y, Xie W, Jankovic J, Le W, Neuroscience 2009 164 2 541 51 10.1016/j.neuroscience.2009.08.014 19682553
30. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, Ye WC, Carcinogenesis 2013 34 6 1331 42 10.1093/carcin/bgt060 23393227
31. A novel image-based cytometry method for autophagy detection in living cells. Chan LL, Shen D, Wilkinson AR, Patton W, Lai N, Chan E, Kuksin D, Lin B, Qiu J, Autophagy 2012 8 9 1371 82 22895056
32. LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. Kabeya Y, Mizushima N, Yamamoto A, Oshitani-Okamoto S, Ohsumi Y, Yoshimori T, J Cell Sci 2004 117 Pt 13 2805 12 15169837 (Pubitemid 38997262)
33. Amino acid regulation of autophagosome formation. Meijer AJ, Methods Mol Biol 2008 445 89 109 10.1007/978-1-59745-157-4-5 18425444
34. Amino acids and insulin control autophagic proteolysis through different signaling pathways in relation to mTOR in isolated rat hepatocytes. Kanazawa T, Taneike I, Akaishi R, Yoshizawa F, Furuya N, Fujimura S, Kadowaki M, J Biol Chem 2004 279 9 8452 9 14610086 (Pubitemid 38294738)
35. Guidelines for the use and interpretation of assays for monitoring autophagy. Klionsky DJ, Abdalla FC, Abeliovich H, et al. Autophagy 2012 8 4 445 544 10.4161/auto.19496 22966490
36. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. Wu YT, Tan HL, Shui G, Bauvy C, Huang Q, Wenk MR, Ong CN, Codogno P, Shen HM, J Biol Chem 2010 285 14 10850 61 10.1074/jbc.M109.080796 20123989
37. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit DB, Rosen N, Cancer Cell 2010 18 1 39 51 10.1016/j.ccr.2010.05.023 20609351
38. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y, Mol Pharmacol 2007 72 1 29 39 10.1124/mol.106.033167 17395690 (Pubitemid 46998522)
39. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Hardie DG, Genes Dev 2011 25 18 1895 908 10.1101/gad.17420111 21937710
40. Renal cancer: Oxygen meets metabolism. Volker HH, Exp Cell Res 2012 318 9 1057 67 10.1016/j.yexcr.2012.02.026 22406000
41. Amino acid inhibition of the autophagic/lysosomal pathway of protein degradation in isolated rat hepatocytes. Seglen PO, Gordon PB, Poli A, Biochim Biophys Acta 1980 630 1 103 1 10.1016/0304-4165(80)90141-5 7388042
42. Regulation and function of autophagy during cell survival and cell death. Das G, Shravage BV, Baehrecke EH, Cold Spring Harb Perspect Biol 2012 4 6 008813 10.1101/cshperspect.a008813 22661635
43. Metabolic stress in autophagy and cell death pathways. Altman BJ, Rathmell JC, Cold Spring Harb Perspect Biol 2012 4 9 008763 10.1101/cshperspect. a008763 22952396
44. Autophagy, stress, and cancer metabolism: what doesn't kill you makes you stronger. Mathew R, White E, Cold Spring Harb Symp Quant Biol 2011 76 389 96 10.1101/sqb.2012.76.011015 22442109
45. Inhibition of active autophagy induces apoptosis and increases chemosensitivity in cholangiocarcinoma. Hou YJ, Dong LW, Tan YX, Yang GZ, Pan YF, Li Z, Tang L, Wang M, Wang Q, Wang HY, Lab Invest 2011 91 8 1146 57 10.1038/labinvest.2011.97 21647092
46. Apoptosis without caspases: an inefficient molecular guillotine? Borner C, Monney L, Cell Death Differ 1999 6 6 497 507 10.1038/sj.cdd.4400525 10381652 (Pubitemid 29292105)
47. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Bäsecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M, McCubrey JA, Aging 2011 3 3 192 222 21422497
48. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F, Int J Cancer 2013 Epub ahead of print
49. Linking ER Stress to Autophagy: Potential Implications for Cancer Therapy. Verfaillie T, Salazar M, Velasco G, Agostinis P, Int J Cell Biol 2010 2010 930509 20145727
50. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA, Giaccia AJ, Cancer Cell 2008 14 1 90 102 10.1016/j.ccr.2008.06.004 18598947 (Pubitemid 351885499)
51. Carminomycin I is an apoptosis inducer that targets the Golgi complex in clear cell renal carcinoma cells. Woldemichael GM, Turbyville TJ, Linehan WM, McMahon JB, Cancer Res 2011 71 1 134 42 10.1158/0008-5472.CAN-10-0757 21199801